Comprehensive Clinical Development Expands Operations, Moves to New Corporate Headquarters
Comprehensive Clinical Development
is pleased to announce the expansion of the Company with the relocation to its corporate headquarters in Miramar, Florida.
The new Miramar, Florida, facility will enable further expansion for the Company’s future growth. Comprehensive has also recently expanded its operational capacity in Tacoma, Washington, with 250 beds. This clinic not only increases capacity for clinical conduct, but broadens access to special populations including oncology and the capability to conduct radiolabeled studies.
“Relocating our corporate headquarters represents an investment in our future,” stated Comprehensive CEO
Jack McGovern
. “We are extremely pleased at the rate Comprehensive is succeeding in this difficult economy and the confidence our clients have in Comprehensive. We are committed to continuing our commitment to quality delivery of clinical development services from our new headquarters. This is another step toward extending our clinical research services, therapeutic areas and customer relationships.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
